Gyre Therapeutics reported a net loss of $2.48 million for the third quarter of 2026, compared to a net income of $1.93 million in the same period of 2025. Total revenues remained relatively flat at $32.93 million, while operating expenses increased significantly, particularly in research and development and general and administrative costs.
Gyre Therapeutics reported Q3 2026 revenue of $32.9 million and affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million. The company is preparing for a potential China NMPA decision on its liver fibrosis candidate F351 by early 2027 and is advancing several protein degrader programs into clinical trials.
Term
Q3 2026
“I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027. Together, these programs are expected to drive our next phase of growth and demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China.”
Dr. Ying Luo, President and Chief Executive Officer